ClinicalTrials.gg
TerminatedNCT06859294Updated Jun 17, 2026

A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis

A Phase 2 interventional study of LY3541860 in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Terminated at 20 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Why this study was terminated
The interim analysis data failed to demonstrate the intended treatment effect.

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Eli Lilly and Company.

Enrollment
28th of 35
35 · median 164
Started
2025
with 1 other
Phase 2
13 of 35
none open now
Registered
33rd of 35
by date

Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 28th largest by enrollment, is one of 2 that started in 2025, is one of 13 in phase 2, and was the 33rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD).

Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) for at least 3 months prior to screening, as defined by the 2010 ACR/EULAR classification criteria.
  • Have moderately to severely active RA, at screening (Visit 1) and baseline (Visit 2), defined by the presence of

    • ≥6 swollen joints based on 66 joint count (and ≥4 swollen joints on 28 joint count), and
    • ≥6 tender joints based on 68 joint count (and ≥4 tender joints on 28 joint count).
  • Have active synovitis in ≥1 joint, in hands or wrists, of the investigator choosing at screening, having an MRI synovitis RAMRIS score of ≥2 as determined from the central reading of the images.

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis or history of malignant disease within 5 years prior to baseline, with the exceptions of

    • basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years, or
    • cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline.
  • Have estimated (eGFR) of \<45 milliliter per minute (mL/minute) from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.
  • Have a current or recent active infection.
  • Have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to

    • poorly controlled diabetes or hypertension
    • chronic kidney disease Stage 3a or b, 4, or 5
    • symptomatic heart failure according to Class 2, 3, or 4
    • myocardial infarction, unstable angina pectoris, stroke, or within the past 12 months before baseline
    • severe chronic pulmonary disease, for example, requiring oxygen therapy major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to
    • systemic lupus erythematosus
    • psoriatic arthritis
    • axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis
    • reactive arthritis
    • gout
    • scleroderma
    • polymyositis
    • dermatomyositis
    • active fibromyalgia, or
    • multiple sclerosis
  • Have received any prior B-cell targeted therapy (for example, anti-CD19 antibodies or anti-CD20 antibodies, such as rituximab).
  • Received , opioids, conventional disease-modifying antirheumatic drug (cDMARD), with changes in dose or have received Janus kinase (JAK) inhibitors within 28 days prior to the screening MRI or plan on receiving these drugs during the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    LY3541860

    LY3541860 will be administered intravenously (IV).

    Drug: LY3541860

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Disease Activity Score - High-Sensitivity C-Reactive Protein (DAS28 - hsCRP)

    DAS28-hsCRP measures disease activity in 28 joints using a composite numeric score. Total scores range from 1.0 to 9.4, where a lower score indicates less disease activity.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change from Baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Synovitis Score

    RAMRIS synovitis score ranges from 0-24, where a lower score indicates a lower level of inflammation.

    Time frame: Baseline, Week 12

  2. Percentage of Participants Achieving American College of Rheumatology (ACR) 20

    ACR20 Responder is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity using VAS, Patient's Global Assessment of Disease Activity using VAS, HAQ-DI, pain due to arthritis, and hsCRP.

    Time frame: Week 12

  3. Percentage of Participants Achieving American College of Rheumatology (ACR) 50

    ACR50 Responder is a participant who has at least 50% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP.

    Time frame: Week 12

  4. Percentage of Participants Achieving American College of Rheumatology (ACR) 70

    ACR70 Responder is a participant who has at least 70% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP.

    Time frame: Week 12

  5. Change from Baseline in Disease Activity Score - Erythrocyte Sedimentation Rate (DAS28 - ESR)

    DAS28-ESR measures disease activity in 28 joints using a composite numeric score. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.

    Time frame: Baseline, Week 12

  6. Percentage of Participants Achieving Low disease activity (LDA) or Remission in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP)

    DAS28-hsCRP measures disease activity in 28 joints using a composite numeric score. Total scores range from 1.0 to 9.4, where a lower score indicates less disease activity. The DAS28-hsCRP LDA is defined as DAS28-hsCRP ≤3.2.

    Time frame: Week 12

  7. Percentage of Participants Achieving European League Against Rheumatism (EULAR) Good Response Criteria

    EULAR Responder index based on 28 joint counts categorizes clinical response based on improvement since baseline in DAS28-hsCRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. EULAR DAS28-hsCRP responder index defines good response criteria as change in DAS28-hSCRP \> 1.2 from baseline with a new DAS28 score \<=3.2.

    Time frame: Week 12

  8. Change from Baseline in ACR Core Set Values Patient's Assessment of Arthritis Pain Using Visual Analog Scale (VAS)

    Participants were asked to assess their current level of arthritis pain by marking a vertical tick on a 100-mm horizontal VAS with the left end (0 mm) marked as "no pain" and the right end (100 mm) marked "worst possible pain."

    Time frame: Baseline, Week 12

  9. Change from Baseline in ACR Core Set Values Patient's Assessment of Physical Function Using Health Assessment Questionnaire - Disability Index (HAQ-DI)

    Participants assess their degree of difficulty of physical function over the past week on a 4-item ordinal scale ranging from 0, "without any difficulty," to 3, "unable to do."

    Time frame: Baseline, Week 12

07

Study locations

20 sites
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale
    Avondale, Arizona 85392, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff
    Flagstaff, Arizona 86001, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa
    Mesa, Arizona 85210, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV
    Phoenix, Arizona 85032, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Sun City
    Sun City, Arizona 85351, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast
    Tucson, Arizona 85748, United States
  • Medvin Clinical Research - Covina
    Covina, California 91722, United States
  • Newport Huntington Medical Group
    Huntington Beach, California 92648, United States
  • Medvin Clinical Research - Tujunga
    Tujunga, California 91042, United States
  • Medvin Clinical Research - Whittier
    Whittier, California 90602, United States
  • Clinical Research of West Florida, Inc. (Clearwater)
    Clearwater, Florida 33765, United States
  • Clinical Research of West Florida
    Tampa, Florida 33606, United States
  • Conquest Research
    Winter Park, Florida 32789, United States
  • Willow Rheumatology and Wellness PLLC
    Willowbrook, Illinois 60527, United States
  • Accurate Clinical Research, Inc
    Lake Charles, Louisiana 70605, United States
  • Saint Paul Rheumatology
    Eagan, Minnesota 55121, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Accurate Clinical Management, LLC
    Baytown, Texas 77521, United States
  • Accurate Clinical Research, Inc
    Houston, Texas 77089, United States
  • DM Clinical Research - TRA
    Tomball, Texas 77375, United States
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Nov 2025, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2025
First posted
Mar 5, 2025
StartActual
Mar 19, 2025
Primary completionActual
Nov 10, 2025
CompletionActual
Jun 5, 2026
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06859294
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
Mar 19, 2025
Primary completion
Nov 10, 2025
Completion
Jun 5, 2026
Last update
Jun 17, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sevoloprubart

Start the discussion